PET Imaging of 68Ga-Her2-affibody in Tumors With High Her2 Expression
- Disease/Condition
- Neoplasms
- Drug/Device/Intervention
- 68Ga-Her2-affibody
- Study type
- Interventional
- Intervention type
- drug
- Primary sponsor
- Peking University First Hospital
- Location
- Beijing, China
- Phase
- N/A
- Start date
- Apr 01, 2024
- End date
- Jun 30, 2025
- Enrollment
- 30 participants
The diagnostic efficacy of 68Ga-Her2-affibody PET/CT in the evaluation of breast cancer
This project uses HER2 protein as the target group of radiodrugs to explore the diagnostic
 efficacy, safety and metabolic characteristics of 68Ga-Her2-affibody in the expression status
 of HER2, aiming to provide a new imaging method for the determination of HER2 status in
 breast cancer At the same time, it also provides new methods and means for early diagnosis,
 accurate staging, recurrence judgment, treatment decision-making and prognosis judgment of
 malignant tumors such as lung cancer, gastrointestinal cancer and bladder cancer, and
 provides scientific basis for precise treatment of malignant tumors.
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT06289517
- Type
- Non-Device Trial
Access comprehensive clinical trial information for NCT06289517 through Pure Global AI's free database. This phase not specified trial is sponsored by Peking University First Hospital and is currently Not yet recruiting. The study focuses on Neoplasms. Target enrollment is 30 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.